Full-Time
Posted on 2/13/2025
Advises on mergers and acquisitions
$105k - $120k/yr
Company Does Not Provide H1B Sponsorship
New York, NY, USA
In Person
People at Lazard who can refer or advise you
Lazard provides financial advisory services for mergers and acquisitions and other corporate finance matters. Its work centers on helping clients plan and execute deals, offering valuation, strategic advice, deal structuring, and negotiating support. A team of experienced bankers and industry specialists draws on a global network to access opportunities and coordinate cross-border transactions. Lazard differentiates itself through deep senior-level involvement, a long track record handling large, complex deals, and a global platform that supports clients across industries. The goal is to help clients maximize value from strategic transactions and complete successful, well-structured deals.
Company Size
N/A
Company Stage
IPO
Headquarters
New York City, New York
Founded
1848
People at Lazard who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Professional Development Budget
Flexible Work Hours
Mental Health Support
Family Planning Benefits
401(k) Company Match
Remote Work Options
Incyte pays $1.25 billion to enter bleeding disorders with Vega acquisition. June 26, 2026 50 views 0 Incyte agreed on June 8 to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25 billion upfront, with up to $750 million more payable on sales milestones, for total potential consideration of up to $2.0 billion. The deal carries the Wilmington, Delaware-based drug company into inherited bleeding disorders, a disease area its existing portfolio does not address. Lazard advised Incyte. Evercore and Morgan Stanley advised Star Therapeutics. The transaction is structured as an equity acquisition and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino Antitrust Improvements Act review. Incyte expects to record an R&D charge of approximately $1.25 billion tied to the deal. Armistice Capital holds a position in Incyte among a broad institutional shareholder base. The Asset: VGA039 in Phase 3 The acquisition centers on VGA039, an investigational monoclonal antibody that targets Protein S to restore the body's clotting capacity. By promoting platelet attachment and enhancing fibrin deposition, VGA039 aims to correct the hemostatic deficiency in patients whose von Willebrand factor is low or dysfunctional. Von Willebrand disease is the most common inherited bleeding disorder in the United States, with roughly 135,000 diagnosed cases. Current prophylactic care for more severe presentations often requires two to three intravenous infusions each week. VGA039 is designed for subcutaneous administration on a once-monthly dosing schedule, a profile that could substantially reduce treatment burden for patients managing a lifelong condition. The drug is in Phase 3 development in the VIVID-6 study and carries Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease designations from the FDA. Bill Meury, Incyte's chief executive, called VGA039 "a first-in-class, Phase 3 asset with a manageable development path" and said it fits directly into Incyte's goal of building a diversified growth company. Incyte's Financial Position Before the Deal Incyte entered the Vega negotiation from a position of strengthening fundamentals. First-quarter 2026 revenue reached $1.27 billion, up 21 percent year over year, with total net sales of $1.10 billion. Jakafi, the myelofibrosis drug that has anchored the company's business for years, posted net sales of $758 million for the quarter. Opzelura cream added $143 million. The hematology and oncology portfolio more than doubled to $204 million on demand for newer products including Niktimvo, Monjuvi, and Zynyz. GAAP net income reached $303 million in the first quarter. Incyte ended the period with $4.0 billion in cash and reaffirmed full-year net sales guidance of $4.77 billion to $4.94 billion. Newer medicines have driven much of the recent growth. Niktimvo, which treats chronic graft-versus-host disease, generated $55 million in first-quarter sales. Monjuvi, the lymphoma therapy, added $49 million. Zynyz, cleared for squamous cell carcinoma of the anal canal and recently approved in Europe for a second indication, contributed $41 million. Building Around Jakafi's Eventual Loss of Exclusivity Jakafi's patent situation has shaped Incyte's planning for several years. The company has pursued four anticipated product approvals and launches over the next 12 months, and in April it reported positive Phase 3 results for povorcitinib in nonsegmental vitiligo alongside an FDA acceptance of the drug's application in hidradenitis suppurativa. An extended-release formulation of Jakafi is also under FDA review with a potential launch expected around mid-year. VGA039 slots into that pipeline as a longer-dated hematology asset rather than a near-term contributor. Hematology, oncology, and inflammation and autoimmunity are the three franchises Incyte has named as its core areas, and VGA039 deepens the first of those at a Phase 3 stage where the drug's mechanism has been validated even as regulatory risk remains. The acquisition adds a program that could generate revenue well beyond Jakafi's exclusivity window, which is the planning horizon Incyte has been working toward. Institutional holders tracking Incyte will ultimately judge the Vega deal against the company's broader portfolio-building effort rather than against the activity of any single institutional participant.
Lazard, Inc. (NYSE: LAZ) today announced that it has entered into a definitive agreement to acquire Campbell Lutyens, a premier global private markets advisor focused on fund placement, secondary advisory, and GP capital advisory services.
Jamie Rubin elected Board Chair of Regional Plan Association. NEW YORK, NY - MARCH 5th, 2026 - By unanimous vote, the Board of Directors of Regional Plan Association (RPA) today has elected Jamie Rubin, Chief Investment Officer at Aligned Climate Capital, as chair of RPA. Mr. Rubin will hold the position for a three-year term and replaces Raymond J. McGuire, President of Lazard. "I want to thank Raymond J. McGuire for his vision and commitment to Chairing the RPA Board," said Tom Wright, President and CEO of Regional Plan Association. "During Ray's tenure we were able to finally implement congestion pricing, celebrate the passage of City of Yes, fully fund the Gateway program, secure operating funds for NJ Transit, and pass statewide housing reform in Connecticut. Ray played an important role in all of these wins, leaving an indelible mark on the future of our metropolitan region." "I am equally excited to welcome Jamie Rubin as RPA's new Chair. Jamie's experience in the public, private and civic sectors will help RPA as we tackle the important infrastructure, housing, and resilience challenges facing our region," Wright continued. "Our work at RPA ultimately impacts how people live: how they get to work, find a home, and feel secure about the future of their communities. Jamie understands that deeply. His leadership and commitment to public service will strengthen our ability to move bold ideas into action, and I'm excited to work alongside him." "Having worked alongside RPA for many years, I've seen firsthand the power of credible, independent analysis to shape the future of our region," said incoming RPA Board Chair, Jamie Rubin. "It is a privilege to step into this role at such a consequential moment. As Chair, I look forward to supporting the organization's outstanding team, strengthening trust in our work, and advancing practical solutions on housing, infrastructure, fiscal stability, and sustainability that will benefit communities across New York, New Jersey, and Connecticut." Jamie Rubin currently serves as Chief Investment Officer at Aligned Climate Capital and Chairman of the Board of the New York City Housing Authority. He has had a long-standing relationship with RPA throughout his career and previously served on the RPA Board and Executive Committee. Mr. Rubin brings more than three decades of experience advancing affordable housing, major infrastructure projects, and clean energy across the public, private, and nonprofit sectors. (See end of document for full bio.) "This appointment comes at a pivotal moment for our region, especially when strong, principled, and respected leadership matters more than ever. Following a comprehensive search process, the board unanimously concluded that Jamie is exceptionally well prepared to be our next leader. I have every confidence that Jamie will build on RPA's achievements and continue advancing the policies and investments that make our communities more sustainable, equitable, and prosperous," said Raymond J. McGuire, Chair of Regional Plan Association's Board of Directors, and President of Lazard. "We sought a leader with strategic insight, collaborative spirit, a deep understanding of the RPA, and the challenges and opportunities facing our region. It's a rare combination, and in Jamie we have found that unique mix. The Search Committee is proud to put forward a candidate who will help guide RPA's next chapter of impact," said RPA Board Chair Search Committee Co-Chairs Shari Hyman and Anthony Shorris. Mr. McGuire will continue to serve as a member of the RPA board of directors. A recommendation by the RPA board executive committee was the result of a several month-long search for a new chair. A board-appointed search committee included seven distinguished members representing the tri-state region and was co-led by Shari Hyman, Vice President, Public Affairs, Turner Construction Company and Co-Chair of the RPA Nominating & Governance Committee; and Anthony Shorris, Partner, McKinsey & Company, and RPA Vice Chair. Jamie Rubin biography: Jamie Rubin has more than three decades of experience working on affordable housing, disaster recovery, major infrastructure projects, and clean energy in the public, private, and nonprofit sectors. He is currently the chief investment officer of Aligned Climate Capital, investing in the low-carbon economy nationally, and previously worked as CEO of Meridiam NA, investing in and developing transformative infrastructure projects, including LaGuardia Airport Terminal B, the Miami Beach monorail, and the D.C. Metro Purple Line extension. He is Chairman of the Board of the New York City Housing Authority (NYCHA), the nation's largest provider of subsidized housing. After many years in finance, Mr. Rubin served from 2013 through 2017 as a top official in New York State government - building and leading the Governor's Office of Storm Recovery to assist homeowners and small businesses while prioritizing long-term resiliency and environmental sustainability and safeguarding against fraud and abuse, overseeing the state's affordable housing strategy as commissioner of New York State Homes and Community Renewal, and overseeing the executive chamber as Director of State Operations. He also served in the federal government as the New York director of President Obama's Hurricane Sandy Recovery and Rebuilding Task Force, a senior advisor to U.S. Housing and Urban Development Secretary Shaun Donovan, and previously in the White House under President Bill Clinton, in the Office of the Chairman of the Federal Communications Commission, as well as on the Obama-Biden presidential transition in 2008. Jamie is the host of the podcast "After Hours with Jamie Rubin: A Vital City Podcast." He is a graduate of Harvard University and Yale Law School. * Sam Bowden Akbari Director of Communications * Christine Hsu Director of Development
Lazard has hired John Koski and Rob Lowe as managing directors in its Healthcare Group, both joining from Allen & Co. The appointments aim to expand Lazard's capabilities in healthcare transactions and sector coverage. Both executives bring extensive healthcare advisory experience, with Koski also contributing a medical background useful for clinically driven mandates. The hires position Lazard to compete more effectively against firms like Goldman Sachs, JPMorgan and Morgan Stanley in healthcare dealmaking. Lazard shares currently trade at $49.16, up 10.2% over the past year. The senior hires will likely add to compensation costs, with benefits dependent on converting relationships into fee income over time.
Lazard expands its Healthcare services team with addition of John Koski and robert Lowe. February 18, 2026 Downloads. NEW YORK, February 18, 2026 - Lazard, Inc. (NYSE: LAZ) today announced that John Koski and Rob Lowe joined the firm in New York as Managing Directors in the Healthcare Group, advising on transactions across the healthcare services sector. These appointments underscore Lazard's continued investment in its Healthcare Group and focus on providing thoughtful, high-quality strategic advice to executives, boards, and investors across the healthcare sector. This announcement also reflects the ongoing momentum behind Lazard's long-term growth strategy, as exceptional bankers are increasingly drawn to the firm's entrepreneurial culture, renowned brand, and global platform. "John and Rob are exceptional advisors with deep sector expertise, a proven track record as thoughtful strategic advisors, and trusted client relationships," said David Gluckman, Global Head of Healthcare at Lazard. "Across the rapidly evolving healthcare services ecosystem, leadership teams, boards and investors face increasing complexity from evolving healthcare policy, dynamic macroeconomic and capital markets conditions, innovative payment models and technological transformation. The addition of John and Rob to our team will further enhance our ability to deliver high-impact, strategic and financial advice, helping our clients to seize opportunities and navigate this changing competitive landscape." Prior to joining Lazard, John served as Managing Director at Allen & Co. where he advised healthcare companies across the healthcare services sector, including payors, providers, distributors, and companies at the intersection of healthcare and technology. Earlier in his career, he was a Resident in Orthopedic Surgery at the Hospital for Special Surgery. John holds an MBA from Harvard Business School, an MD from the Yale School of Medicine, and a BA in Biology from Harvard University. "I am excited to join Lazard's Healthcare team, a platform known for its deep sector expertise and commitment to delivering thoughtful, high-impact advice. The firm's entrepreneurial culture and global reach create a compelling opportunity to support clients as they navigate a rapidly evolving healthcare landscape," said John Koski. Rob also joins Lazard from Allen & Co., where he was a Managing Director, advising on transactions across healthcare, including payors, providers, distributors, and companies at the intersection of healthcare and technology. Previously, Rob served as a Director in Healthcare at Citi as part of the Global Healthcare Investment Banking Group. He earned his MBA from NYU Stern and his bachelor's degree from Colgate University. "Lazard's Healthcare franchise offers a unique combination of strategic insight, client focus, and a highly collaborative environment. I am thrilled to join this team and help build on its strong momentum, partnering with clients to capitalize on growth opportunities and address today's dynamic healthcare ecosystem," said Rob Lowe. About Lazard Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn. Media Contact Jessica Francisco Media Contact Shannon Houston INVESTOR CONTACT Alexandra Deignan More news & announcements. February 02, 2026 Press releases January 29, 2026 Press releases January 29, 2026 Press releases